Compare OLB & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | RNAZ |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.5M |
| IPO Year | 2019 | 2021 |
| Metric | OLB | RNAZ |
|---|---|---|
| Price | $0.43 | $8.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 351.4K | 5.4K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.48 | 54.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,676,907.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.22 |
| 52 Week High | $2.50 | $20.99 |
| Indicator | OLB | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 43.58 |
| Support Level | $0.31 | $8.37 |
| Resistance Level | $0.58 | $11.62 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 24.77 | 28.03 |
The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise. It focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. Along with its subsidiaries, the company offers a cloud-based business management platform that provides turnkey solutions for merchants to enable them to build and manage their retail businesses, whether online or at a brick-and-mortar location, payment processing solutions, payment gateway, virtual terminal with proprietary business management tools, and crowdfunding solutions. The company has two business segments; Fintech Services which generates key revenue, and the Bitcoin Mining business segment.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.